Cbl-independent degradation of Met: Ways to avoid agonism of bivalent met-targeting antibody

Oncogene

Volumn 33, Issue 1, 2014, Pages 34-43

  Lee, J M ^a   Kim, B ^a   Lee, S B ^a   Jeong, Y ^a   Oh, Y M ^a   Song, Y J ^a   Jung, S ^a   Choi, J ^a   Lee, S ^a   Cheong, K H ^a   Kim, D U ^a   Park, H W ^a   Han, Y K ^a   Kim, G W ^a   Choi, H ^a   Song, P H ^a   Kim, K A ^a  

^a SAMSUNG Electronics   (South Korea)

Author keywords

agonism; Cbl; LRIG1; Met; SAIT301

Indexed keywords

ANTINEOPLASTIC AGENT; CBL PROTEIN; LRIG1 PROTEIN; MONOCLONAL ANTIBODY; REGULATOR PROTEIN; SAIT 301; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; EXON; GENE DELETION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

EID: 84891742197     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.551     Document Type: Article

References (44)

1. Crepaldi T, Pollack AL, Prat M, Zborek A, Mostov K, Comoglio PM. Targeting of the SF/HGF receptor to the basolateral domain of polarized epithelial cells. J Cell Biol 1994; 125: 313-320. (Pubitemid 24135945)
2. Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 1991; 10: 2867-2878. (Pubitemid 21905304)
3. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-925. (Pubitemid 37493640)
4. Comoglio PM, Boccaccio C. Scatter factors and invasive growth. Semin Cancer Biol 2001; 11: 153-165. (Pubitemid 32423290)
5. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834-848.
6. Petrelli A, Gilestro GF, Lanzardo S, Comoglio PM, Migone N, Giordano S. The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature 2002; 416: 187-190. (Pubitemid 34246477)
7. Qin S, Taglienti M, Nauli SM, Contrino L, Takakura A, Zhou J et al. Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease. J Clin Invest 2010; 120: 3617-3628.
8. Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009; 460: 904-908.
9. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003; 63: 6272-6281. (Pubitemid 37255174)
10. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 2009; 4: 5-11.
11. Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006; 66: 283-289. (Pubitemid 43166034)
12. Zang ZJ, Ong CK, Cutcutache I, Yu W, Zhang SL, Huang D et al. Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. Cancer Res 2011; 71: 29-39.
13. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 2008; 105: 692-697. (Pubitemid 351171770)
14. Lai AZ, Durrant M, Zuo D, Ratcliffe CD, Park M. Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer. J Biol Chem 2012; 287: 8048-8059.
15. Lefebvre J, Ancot F, Leroy C, Muharram G, Lemiere A, Tulasne D. Met degradation: more than one stone to shoot a receptor down. FASEB J 2012; 26: 1387-1399.
16. Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 2010; 16: 37-45.
17. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006; 103: 2316-2321. (Pubitemid 43271667)
18. Foveau B, Ancot F, Leroy C, Petrelli A, Reiss K, Vingtdeux V et al. Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell 2009; 20: 2495-2507.
19. Nakagawa T, Tohyama O, Yamaguchi A, Matsushima T, Takahashi K, Funasaka S et al. E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci 2010; 101: 210-215.
20. Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012; 2: 270-287.
21. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7: 504-516. (Pubitemid 351767118)
22. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15: 2207-2214.
23. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006; 12: 3657-3660. (Pubitemid 44000247)
24. Stellrecht CM, Gandhi V. MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett 2009; 280: 1-14.
25. Vigna E, Pacchiana G, Mazzone M, Chiriaco C, Fontani L, Basilico C et al. 'Active' cancer immunotherapy by anti-Met antibody gene transfer. Cancer Res 2008; 68: 9176-9183.
26. Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H et al. MetMAb, the onearmed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68: 4360-4368.
27. Hedman H, Henriksson R. LRIG inhibitors of growth factor signalling-doubleedged swords in human cancer Eur J Cancer 2007; 43: 676-682. (Pubitemid 46502902)
28. Ordonez-Moran P, Huelsken J. Lrig1: a new master regulator of epithelial stem cells. EMBO J 2012; 31: 2064-2066.
29. Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, Carraway 3rd KL et al. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 2007; 27: 1934-1946.
30. Krumbach R, Schuler J, Hofmann M, Giesemann T, Fiebig HH, Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer 2011; 47: 1231-1243.
31. Oh YM, Song Y, Lee SB, Jeong Y, Kim B, Kim GW et al. A novel anti-c-Met antibody: therapeutic potential in cancer. Mol Cells (accepted).
32. Stutz MA, Shattuck DL, Laederich MB, Carraway III KL, Sweeney C. LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene 2008; 27: 5741-5752.
33. Wong VW, Stange DE, Page ME, Buczacki S, Wabik A, Itami S et al. Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nat Cell Biol 2012; 14: 401-408.
34. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 2007; 213: 316-325. (Pubitemid 47509708)
35. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
36. Petrelli A, Circosta P, Granziero L, Mazzone M, Pisacane A, Fenoglio S et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci USA 2006; 103: 5090-5095.
37. Pacchiana G, Chiriaco C, Stella MC, Petronzelli F, De Santis R, Galluzzo M et al. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J Biol Chem 2010; 285: 36149-36157.
38. Schelter F, Kobuch J, Moss ML, Becherer JD, Comoglio PM, Boccaccio C et al. A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. J Biol Chem 2010; 285: 26335-26340.
39. Ancot F, Leroy C, Muharram G, Lefebvre J, Vicogne J, Lemiere A et al. Shedding-Generated Met Receptor Fragments can be Routed to Either the Proteasomal or the Lysosomal Degradation Pathway. Traffic 2012; 13: 1261-1272.
40. Greenall SA, Gherardi E, Liu Z, Donoghue JF, Vitali AA, Li Q et al. Nonagonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET. PLoS One 2012; 7: e34658.
41. Asaoka Y, Tada M, Ikenoue T, Seto M, Imai M, Miyabayashi K et al. Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. Biochem Biophys Res Commun 2010; 394: 1042-1046.
42. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104: 20932-20937.
43. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043. (Pubitemid 46799492)
44. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977; 197: 461-463.